Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

VolitionRx (NYSE: VNRX)

Last close As at 22/11/2024

USD0.81

— 0.00 (0.12%)

Market capitalisation

USD76m

VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

Latest Insights

View More

Healthcare | edison tv

Volition webinar: Nu.Q NETs data insights

Healthcare | edison tv

VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

Healthcare | Update

VolitionRx — Snaring sepsis, with early NETs detection

Healthcare | edison tv

VolitionRx webinar: Breakthrough liquid biopsy method for cancer detection
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • Cameron Reynolds

    CEO

  • Jake Micallef

    Chief Scientific Officer

  • Scott Powell

    Director of IR

  • Terig Hughes

    CFO

Balance Sheet

Forecast net debt (US$m)

1.6

Forecast gearing ratio (%)

94

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 10.5 22.5 10.9
Relative 9.6 15.9 (14.8)
52 week high/low US$1.2/US$0.5

Financials

VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These efforts, coupled with its CE mark in Europe, are a strong foundation in rapid and simplified sepsis detection that seeks to address the limitations and complexities of the current standard of care. Sepsis (immune-system triggered organ dysfunction) has a worrisome prevalence, affecting c 50 million per year with a mortality rate of c 20–25%, exceeding the combination of many leading cancers. Further, every hour of delayed treatment increases the chances of mortality of this preventable condition by c 8%. In this note we recap VolitionRx’s recent clinical updates, as we look forward to near-term improvements in early sepsis detection.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2018A 0.0 (17.9) (18.0) (57.37) N/A N/A
2019A 0.0 (16.1) (16.1) (41.09) N/A N/A
2020E 0.0 (17.2) (17.4) (42.61) N/A N/A
2021E 0.1 (18.6) (18.8) (44.46) N/A N/A

Research

edison tv

Healthcare

VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

Update

Healthcare

VolitionRx — Snaring sepsis, with early NETs detection

Healthcare

edison tv

Volition webinar: Nu.Q NETs data insights
View All

Further insights

insight

Healthcare

VolitionRx – On the cusp of a breakthrough in testing for sepsis

insight

Healthcare

Volition: Views from the sharp end

insight

Healthcare

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

insight

Healthcare

Healthcare Week 2023

insight

Healthcare

Volition signs global supply agreement for Nu.Q® Vet Cancer Test

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free